avelumab
E822413
Avelumab is a human monoclonal antibody immunotherapy drug used to treat certain cancers by blocking the PD-L1 immune checkpoint pathway.
All labels observed (1)
| Label | Occurrences |
|---|---|
| avelumab canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T9807402 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: avelumab Context triple: [programmed death-ligand 1, targetOfDrug, avelumab]
-
A.
ansuvimab
Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
-
B.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
C.
Libtayo
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
-
D.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
E.
Alecensa
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: avelumab Target entity description: Avelumab is a human monoclonal antibody immunotherapy drug used to treat certain cancers by blocking the PD-L1 immune checkpoint pathway.
-
A.
ansuvimab
Ansuvimab is a monoclonal antibody used as a therapeutic treatment for infection caused by Zaire ebolavirus (Ebola virus).
-
B.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
C.
Libtayo
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
-
D.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
E.
Alecensa
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
antineoplastic agent
ⓘ
immunotherapy drug ⓘ monoclonal antibody ⓘ |
| administrationSetting | healthcare facility ⓘ |
| antibodyType | IgG1 ⓘ |
| belongsTo | checkpoint inhibitor therapies ⓘ |
| bindsTo | programmed death-ligand 1 ⓘ |
| combinationIndication | first-line treatment of advanced renal cell carcinoma with axitinib ⓘ |
| commonAdverseEffect |
diarrhea
ⓘ
fatigue ⓘ infusion-related reactions ⓘ nausea ⓘ rash ⓘ |
| contraindicationCaution | severe immune-mediated toxicity history ⓘ |
| developedBy |
Merck KGaA
ⓘ
Pfizer ⓘ |
| dosingSchedule | every 2 weeks in many indications ⓘ |
| firstFDAApprovalYear | 2017 ⓘ |
| hasATCCode | L01FF03 ⓘ |
| hasGenericName | avelumab ⓘ |
| hasHalfLifeApprox | 6 days to 7 days ⓘ |
| hasTradeName | Bavencio ⓘ |
| immuneRelatedAdverseEffect |
colitis
ⓘ
endocrinopathies ⓘ hepatitis ⓘ pneumonitis ⓘ |
| indicationRegion |
European Union
ⓘ
United States ⓘ
linked to:
United States of America
|
| indicationType | oncology ⓘ |
| isFullyHuman | true ⓘ |
| isHuman | true ⓘ |
| isPrescriptionOnly | true ⓘ |
| isRecombinant | true ⓘ |
| mechanismOfAction |
blocks PD-1/PD-L1 interaction
ⓘ
enhances T-cell mediated immune response against tumor cells ⓘ |
| pharmacologicClass | PD-L1 blocking antibody ⓘ |
| regulatoryApproval |
EMA-approved
ⓘ
FDA-approved ⓘ |
| requiresMonitoringFor | immune-mediated adverse reactions ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targets |
PD-L1
ⓘ
linked to:
programmed death-ligand 1
|
| treats |
locally advanced Merkel cell carcinoma
ⓘ
locally advanced renal cell carcinoma ⓘ locally advanced urothelial carcinoma ⓘ metastatic Merkel cell carcinoma ⓘ metastatic renal cell carcinoma ⓘ metastatic urothelial carcinoma ⓘ |
| usedInCombinationWith | axitinib ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: avelumab Description of subject: Avelumab is a human monoclonal antibody immunotherapy drug used to treat certain cancers by blocking the PD-L1 immune checkpoint pathway.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.